Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75030
UPID:
MITF_HUMAN
Alternative names:
Class E basic helix-loop-helix protein 32
Alternative UPACC:
O75030; B4DJL2; D3K197; E9PFN0; Q14841; Q9P2V0; Q9P2V1; Q9P2V2; Q9P2Y8
Background:
Microphthalmia-associated transcription factor, also known as Class E basic helix-loop-helix protein 32, plays a pivotal role in cell differentiation, proliferation, and survival. It regulates the expression of genes crucial for melanocyte development, including tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1), by binding to specific DNA sequences in their promoters.
Therapeutic significance:
Linked to diseases such as Waardenburg syndrome 2A, Tietz albinism-deafness syndrome, cutaneous malignant melanoma 8, and COMMAD syndrome, understanding the role of Microphthalmia-associated transcription factor could open doors to potential therapeutic strategies. Its involvement in pigmentary disturbances and sensorineural deafness highlights its therapeutic potential.